Augmentation of leukocyte infiltration in murine tumors expressing b- cell derived but not nasopharyngeal carcinoma derived EBV membrane protein LMP1

Journal of Medical Virology

Volumn 60, Issue 4, 2000, Pages 417-424

  Trivedi, Pankaj ^a,d   Cuomo, Laura ^b   Christensson, Birger ^c   Li Fu, Hu ^a   Morrone, Stefania ^d   Frati, Luigi ^b,d   Faggioni, Alberto ^d   Winberg, Gösta ^a   Klein, George ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IRCCS NEUROMED   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BL; EBV; Leukocytes; LMPI; NPC

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LATENT MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CARCINOMA CELL; CELL INFILTRATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INOCULATION; LEUKOCYTE; MALIGNANT TRANSFORMATION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; SKIN NECROSIS; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS CARCINOGENESIS;

ANIMALS; ANTIGENS, CD80; ANTIGENS, VIRAL; B-LYMPHOCYTES; CAPSID; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; NEUTROPHIL INFILTRATION; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 4; MURINAE;

EID: 0034001431     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200004)60:4<417::AID-JMV9>3.0.CO;2-O     Document Type: Article

References (40)

1. Avila-Carino J, Torsteindottir S, Ehlin-Henriksson B, Lenoir G, Klein G, Klein E, Masucci MG. 1987. Paired Epstein-Barr virus-negative and EBV converted Burkitt lymphoma lines: stimulatory capacity in allogeneic mixed lymphocyte cultures. Int J Cancer 40:691-697.
2. Baskar S, Glimcher L, Nabavi N, Jones RT, Rosenberg-Ostrand S. 1995. Major histocompatibility complex Class II + B7 + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619-629.
3. Chen F, Hu LF, Ernberg I, Klein G, Winberg G. 1995. Coupled transcription of Epstein-Barr virus LMP1 and LMP2A genes in nasopharyngeal carcinomas. J Gen Virol 76:131-138.
4. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. 1991. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88:110-114.
5. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I, Hellstrom KE. 1992. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148:2617-2621.
6. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T-cell mediated immunity. J Exp Med 179:523-532.
7. Cherney BW, Sgadari C, Kanegane C, Wang F, Tosato G. 1998. Expression of Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 91:2491-2499.
8. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56:2531-2534.
9. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. 1993. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 177:1127-1134.
10. Cuomo L, Ramquist T, Trivedi P, Wang F, Klein G, Masucci MG. 1992. Expression of the Epstein-Barr virus (EBV) encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV negative Burkitt lymphoma line. Int J Cancer 51:949-955.
11. Dolcetti R, Frisan T, Sjoberg J, De Campos-Lima PO, Pisa P, De Re V, Gloghini A, Rizzo S, Masucci MG, Boiocchi M. 1995. Identification and characterization of an Epstein-Barr virus specific T-cell response in pathologic tissue of a patient with Hodgkin's disease. Cancer Res 54:3675-3681.
12. Fahraeus R, Hu LF, Ernberg I, Finke J, Rowe M, Klein G, Falk K., Nilsson E, Yadav M, Busson P, Tursz T, Kallin B. 1988. Expression of Epstein-Barr virus encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42:329-338.
13. Floettmann JE, Ward K, Rickinson AB, Rowe M. 1996. Cytostatic effect of Epstein-Barr virus encoded LMP1 analyzed using tetracycline regulated expression in B cell lines. Virology 223:29-40.
14. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone M, Brautbar C, Battat S, Biberfeld P, Eckman M, Pisa P, Masucci MG. 1995. Local suppression of Epstein-Barr virus (EBV) specific cytotoxicity in biopsies of EBV positive Hodgkin's disease. Blood 86:1493-1497.
15. Gavioli R, de Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG. 1992. Recognition of the EBV encoded nuclear antigens EBNA-4 and EBNA-6 by HLA A11 restricted cytotoxic T lymphocytes: implications for the down regulation of HLA A11 in the Burkitt lymphoma. Proc Natl Acad Sci USA 89:5862-5866.
16. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. 1988. Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus positive Burkitt lymphoma underlies tumor cell escape from specific T-cell surveillance. J Exp Med 167:1811-1824.
17. Hu LF, Zabarowsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G. 1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72:2399-2409.
18. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, Klein G, Winberg G. 1993. Clonability and tumorigenicity of human epithelial cells expressing EBV encoded membrane protein LMP1. Oncogene 8:1575-1580.
19. Huang YT, Sheen TS, Chen CL, Lu J, Chang Y, Chen JY, Tsai CH. 1999. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res 59:1599-1605.
20. Kieff E, Liebowitz D. 1989. The Epstein-Barr virus. In: Fields B. Knipe D, editors. Virology. New York: Raven Press, p 1889-1929.
21. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942.
22. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176:169-176.
23. Kuzumaki N, More IAR, Cochran AJ, Klein G. 1980. Thirteen new mammary tumor cell lines from different mouse strains. Eur J Cancer 16:1181-1192.
24. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a wide range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428-7434.
25. Litton M, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U. 1996. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production and apoptosis in human colon carcinoma. Eur J Immunol 26:1-10.
26. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. 1992. The origin and function of tumor associated macrophages. Immunol Today 13:265-270.
27. Masucci MG, Ernberg I. 1995. Epstein-Barr virus: adaptation to a life within immune system. Trends Microbiol 2:125-130.
28. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176:157-168.
29. Opdenakker G, Van Damme G. 1992. Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 13:463-464.
30. O'Sullivan C, Lewis CE. 1994. Tumor associated leukocytes: friends or foes in breast carcinoma. J Pathol 172:229-235.
31. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows S, Moss DJ, Rickinson AB. 1995. Restoration of endogenous antigen processing in Burkitt lymphoma cells by Epstein-Barr virus LMP1: coordinate upregulation of peptide transporters and HLA Class I expression. Eur J Immunol 25:1373-1384.
32. Stoppacciaro A, Paglia P, Lombardi L, Parmiani G, Baroni C, Colombo MP. 1997. Genetic modification of a carcinoma with IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 27:2375-2382.
33. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hinibo H, Hamada H, Azuma M, Asano S. 1997. GM-CSF and B7-1 (CD80) co-stimulatory signals cooperate in the induction of effective anti-tumor immunity in syngeneic mice. Int J Cancer 73:556-561.
34. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. 1979. Procedures and some applications. Proc Natl Acad Sci USA 76:4350-4354.
35. Trivedi P, Hu LF, Chen F, Christensson B, Masucci MG, Klein G, Winberg G. 1994. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system in contrast to a B-cell derived homologue. Eur J Cancer 30A:84-88.
36. Trivedi P, Masucci MG, Winberg G, Klein G. 1991. The EBV encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of the transfected murine mammary carcinoma cells. Int J Cancer 48:794-800.
37. Wallace LE, Rickinson AB, Rowe M, Epstein MA. 1985. Epstein Barr virus cytotoxic T cell clones restricted through a single HLA antigen. Nature 297:413-415.
38. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB. 1988. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69:1051-1065.
39. Zhang Q, Brooks L, Bussen P, Wang F, Kieff E, Rickinson AB, Tursz T. 1995. Epstein-Barr virus latent membrane protein LMP1 increases HLA Class II expression in an EBV negative B cell line. Eur J Immunol 24:1467-1470.
40. Zhong YS, Lin H, Choy DT, Sham JS, Wei W, Chan KH, Ng MH. 1991. Nasopharyngeal carcinoma and lymphoinfiltration. Oncology 48: 290-296.